Ovid Therapeutics Inc. (OVID) Reports In-Line Q1 EPS

Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q1 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $130 thousand versus the consensus estimate of $79.6 thousand.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c